Solu-Medrol Indications/Uses

Methylprednisolone sodium succinate (Solu-Medrol) is indicated in the following conditions: Endocrine Disorders: primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present (when mineralocorticoid activity is undesirable); preoperatively, or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated with cancer.
Rheumatic Disorders (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation): post-traumatic osteoarthritis; synovitis of osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis; acute and subacute bursitis; epicondylitis; acute non-specific tenosynovitis; acute gouty arthritis; psoriatic arthritis; ankylosing spondylitis.
Collagen Diseases and Immune Complex Diseases (during an exacerbation or as maintenance therapy in selected cases): systemic lupus erythematosus (and lupus nephritis); acute rheumatic carditis; systemic dermatomyositis (polymyositis); polyarteritis nodosa; Goodpasture's syndrome.
Dermatologic Diseases: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; severe psoriasis; bullous dermatitis herpetiformis; severe seborrheic dermatitis; mycosis fungoides.
Allergic States (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment): bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions; urticarial transfusion reactions; acute non-infectious laryngeal edema.
Ophthalmic Diseases (severe acute and chronic allergic and inflammatory processes involving the eye): herpes zoster ophthalmicus; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; anterior segment inflammation; allergic conjunctivitis; allergic corneal marginal ulcers; keratitis.
Gastrointestinal Diseases (to manage critical periods of the disease): ulcerative colitis; regional enteritis.
Respiratory Diseases: symptomatic sarcoidosis; berylliosis; fulminating or disseminated tuberculosis (when used concurrently with appropriate antituberculous chemotherapy); Loeffler's syndrome not manageable by other means; aspiration pneumonitis; moderate to severe Pneumocystis jiroveci pneumonia in AIDS patients (as adjunctive therapy when given within the first 72 hours of initial anti-pneumocystis treatment); exacerbations of chronic obstructive pulmonary disease (COPD).
Hematologic Disorders: acquired (autoimmune) hemolytic anemia; idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia.
Neoplastic Diseases (palliative management): leukemias and lymphomas in adults; acute leukemia of childhood; to improve quality of life in patients with terminal cancer.
Edematous States: to induce diuresis or remission of proteinuria in the nephrotic syndrome without uremia.
Nervous System: cerebral edema from primary or metastatic tumors or surgical or radiation therapy; acute exacerbations of multiple sclerosis; acute spinal cord injury.
The treatment should begin within 8 hours of injury.
Other Indications: tuberculous meningitis with subarachnoid block or impending block (when used concurrently with appropriate antituberculous chemotherapy); trichinosis with neurologic or myocardial involvement; organ transplantation; prevention of nausea and vomiting associated with cancer chemotherapy.